FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023244835> ?p ?o ?g. }

• W2023244835 endingPage "693" @default.
• W2023244835 startingPage "683" @default.
• W2023244835 abstract "We investigated the safety and immunogenicity of a candidate HIV-1 vaccine, Env 2-3 (Chiron Biocine Co.), in combination with an adjuvant emulsion, MF59, with or without an additional immune modulator, MTP-PE, in 78 healthy HIV-1-seronegative adults. Sixteen subjects participated in a dose escalation study of MTP-PE in MF59 without Env 2-3, given at 0 and 1 months; 48 subjects participated in a study of a fixed dose of 30 μg of Env 2-3 in MF59 with increasing doses of MTP-PE (0, 5, 10, 25, 50, and 100 μg), and 14 subjects participated in a study of 100 μg of Env 2-3 in MF59 without MTP-PE. Subjects were assigned to study groups under a randomized, double-blind allocation. Subjects received immunization at 0, 1, and 6 months, and had the option of receiving a fourth dose at 12–18 months. Env 2-3 in MTP-PE/MF59 was associated with significant reactogenicity, in that severe, although self-limited systemic and/or local reactions occurred in 15 of 30 vaccinees. In contrast, Env 2-3 in MF59 without MTP-PE was relatively well tolerated, and severe local and/or systemic reactions occurred in only 2 of 18 subjects. Env 2-3 stimulated serum antibodies to HIV-1 envelope protein (gp120) as detected by Western blot in 39 of 43 subjects and to HIV-1 virus lysate by EIA in 28 of 43 subjects after three injections. The majority of subjects also developed EIA antibodies to recombinant gp120 (SF-2), gp120 (LAI), and V3 peptide (SF-2). Neutralizing antibodies to the homologous SF-2 strain developed in 30 of 43 and 27 of 34 subjects, and fusion inhibition antibodies in 25 of 43 and 15 of 36 subjects after three and four injections, respectively. Lymphoproliferative responses to the immunogen, Env 2-3, were observed in over 80% of the vaccinees examined, and CD4+ cytotoxic T cell activity directed against HIV-1 was noted transiently in 2 of 20 vaccinees. Addition of MTP-PE to Env 2-3 or increasing the dose of Env 2-3 from 30 to 100 μg did not augment immunogenicity. Env 2-3 in MF59 was well tolerated and immunogenic in HIV-1-seronegative individuals. The addition of MTP-PE significantly increased reactogenicity, but had little, if any, effect on immunogenicity." @default.
• W2023244835 created "2016-06-24" @default.
• W2023244835 creator A5002707102 @default.
• W2023244835 creator A5008691315 @default.
• W2023244835 creator A5010176480 @default.
• W2023244835 creator A5011603375 @default.
• W2023244835 creator A5013153304 @default.
• W2023244835 creator A5021608465 @default.
• W2023244835 creator A5023660900 @default.
• W2023244835 creator A5029359442 @default.
• W2023244835 creator A5029754146 @default.
• W2023244835 creator A5043571794 @default.
• W2023244835 creator A5046105449 @default.
• W2023244835 creator A5055605804 @default.
• W2023244835 creator A5083165826 @default.
• W2023244835 creator A5084520588 @default.
• W2023244835 date "1996-05-20" @default.
• W2023244835 modified "2023-09-27" @default.
• W2023244835 title "Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59" @default.
• W2023244835 cites W1661825545 @default.
• W2023244835 cites W1912026111 @default.
• W2023244835 cites W1978875436 @default.
• W2023244835 cites W1992657362 @default.
• W2023244835 cites W1995977258 @default.
• W2023244835 cites W2007583829 @default.
• W2023244835 cites W2015491589 @default.
• W2023244835 cites W2044263461 @default.
• W2023244835 cites W2046820194 @default.
• W2023244835 cites W2051589676 @default.
• W2023244835 cites W2052220933 @default.
• W2023244835 cites W2053798163 @default.
• W2023244835 cites W2070002398 @default.
• W2023244835 cites W2073024817 @default.
• W2023244835 cites W2075674637 @default.
• W2023244835 cites W2075924967 @default.
• W2023244835 cites W2092985132 @default.
• W2023244835 cites W2105832966 @default.
• W2023244835 cites W2116372466 @default.
• W2023244835 cites W2151290414 @default.
• W2023244835 cites W2155131772 @default.
• W2023244835 cites W2156557297 @default.
• W2023244835 cites W2166853310 @default.
• W2023244835 cites W2170908973 @default.
• W2023244835 cites W287737851 @default.
• W2023244835 cites W4243272960 @default.
• W2023244835 doi "https://doi.org/10.1089/aid.1996.12.683" @default.
• W2023244835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8744579" @default.
• W2023244835 hasPublicationYear "1996" @default.
• W2023244835 type Work @default.
• W2023244835 sameAs 2023244835 @default.
• W2023244835 citedByCount "66" @default.
• W2023244835 countsByYear W20232448352012 @default.
• W2023244835 countsByYear W20232448352013 @default.
• W2023244835 countsByYear W20232448352014 @default.
• W2023244835 countsByYear W20232448352017 @default.
• W2023244835 countsByYear W20232448352019 @default.
• W2023244835 countsByYear W20232448352020 @default.
• W2023244835 countsByYear W20232448352021 @default.
• W2023244835 crossrefType "journal-article" @default.
• W2023244835 hasAuthorship W2023244835A5002707102 @default.
• W2023244835 hasAuthorship W2023244835A5008691315 @default.
• W2023244835 hasAuthorship W2023244835A5010176480 @default.
• W2023244835 hasAuthorship W2023244835A5011603375 @default.
• W2023244835 hasAuthorship W2023244835A5013153304 @default.
• W2023244835 hasAuthorship W2023244835A5021608465 @default.
• W2023244835 hasAuthorship W2023244835A5023660900 @default.
• W2023244835 hasAuthorship W2023244835A5029359442 @default.
• W2023244835 hasAuthorship W2023244835A5029754146 @default.
• W2023244835 hasAuthorship W2023244835A5043571794 @default.
• W2023244835 hasAuthorship W2023244835A5046105449 @default.
• W2023244835 hasAuthorship W2023244835A5055605804 @default.
• W2023244835 hasAuthorship W2023244835A5083165826 @default.
• W2023244835 hasAuthorship W2023244835A5084520588 @default.
• W2023244835 hasConcept C126322002 @default.
• W2023244835 hasConcept C159047783 @default.
• W2023244835 hasConcept C159654299 @default.
• W2023244835 hasConcept C203014093 @default.
• W2023244835 hasConcept C2777704310 @default.
• W2023244835 hasConcept C2777863537 @default.
• W2023244835 hasConcept C2780648854 @default.
• W2023244835 hasConcept C2780801004 @default.
• W2023244835 hasConcept C2780868878 @default.
• W2023244835 hasConcept C71924100 @default.
• W2023244835 hasConceptScore W2023244835C126322002 @default.
• W2023244835 hasConceptScore W2023244835C159047783 @default.
• W2023244835 hasConceptScore W2023244835C159654299 @default.
• W2023244835 hasConceptScore W2023244835C203014093 @default.
• W2023244835 hasConceptScore W2023244835C2777704310 @default.
• W2023244835 hasConceptScore W2023244835C2777863537 @default.
• W2023244835 hasConceptScore W2023244835C2780648854 @default.
• W2023244835 hasConceptScore W2023244835C2780801004 @default.
• W2023244835 hasConceptScore W2023244835C2780868878 @default.
• W2023244835 hasConceptScore W2023244835C71924100 @default.
• W2023244835 hasIssue "8" @default.
• W2023244835 hasLocation W20232448351 @default.
• W2023244835 hasLocation W20232448352 @default.
• W2023244835 hasOpenAccess W2023244835 @default.
• W2023244835 hasPrimaryLocation W20232448351 @default.

• next